Oppenheimer On Insys Therapeutics, Says While DoJ Investigation Appears To Be Near Settlement, Firm Still Believes Subsys Sales Estimates Too High; Says They Are Generally Positive On Insys Cannabidiol Platform
Paul Quintaro